Document Type : Original Article
Authors
- . Zohreh Ghorbani 1
- . Seyed Morteza Shamshirgaran 2
- . Samad Ghaffari 3
- . Parvin Sarbakhsh 4
- . Farzad Najafipour 5
- . Nayyereh Aminisani 1
1 Department of Statistics and Epidemiology, School of Health Sciences, Tabriz University of Medical Sciences
2 Department of Statistics and Epidemiology, School of Health Sciences, Tabriz University of Medical Sciences, Injury Epidemiology Prevention Research Centre, School of Health Sciences, Tabriz University of Medical Sciences,
3 Cardiovascular Research Centre, Tabriz University of Medical Sciences
4 Injury Epidemiology Prevention Research Centre, School of Health Sciences, Tabriz University of Medical Sciences, 3
5 Endocrine Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
BACKGROUND AND OBJECTIVE: There is remarkable alteration in hypertension prevalence
and awareness, and their correlates among various geographic locations and ethnic groups. The
aim of this study was to report hypertension prevalence, awareness, and its correlates as well as
hypertension treatment, and control among Azari people aged 35 years and older.
MATERIALS AND METHODS: The pilot phase of the Azar Cohort Study; a state level of a nationwide
PERSIAN cohort study was conducted in Khameneh city between October 2014 and January 2015.
All people 35 years of age and above were invited to take part in this study. A comprehensive range of
different biomarkers, lifestyle, socioeconomic factors, and health‑related factors was collected. Blood
pressure was measured by a trained nurse/midwife. Descriptive statistical methods were used to present
general characteristics of the study population as frequency tables. Separate multiple logistic regression
models were built to assess the predictors of hypertension prevalence.
RESULTS: A total of 1038 people were included in this study. The overall prevalence of hypertension
was 22.9%. Awareness of hypertension was 60.5% and in those with known hypertension, 84% were
using the antihypertensive medications, of those 68.5% had controlled hypertension. After adjustment;
age (odds ratios [OR] adj = 1.12 95% confidence interval [CI]: 1.09–1.15), gender (ORadj = 1.65 95% CI:
1.08–2.51), obesity ORadj = 2.51 (1.40–4.88), waist‑to‑hip ratio (WHR) (ORadj = 1.70 (1.05–2.75), and
comorbidities (ORadj = 2.51 (1.72–3.66) were independent predictors of hypertension.
CONCLUSION: Age, sex, body mass index, WHR, and comorbidities were known as predictors
of hypertension in this study, health promotion strategies including lifestyle modification to reduce
overweight/obesity and secondary prevention programs for early detection of hypertension in high‑risk
groups according to age, gender, and disease profile are recommended.
Keywords
Hekmatdoost A, et al. Prospective epidemiological research
studies in irAN (The PERSIAN cohort): Rationale, objectives and
design. Am J Epidemiol 2017.
2. Braunwald E, Hollenberg NK. Atlas of Hypertension. California
USA: Springer Science & Business Media; 2012.
3. Eyre H, Kahn R, Robertson RM, Clark NG, Doyle C, Hong Y,
et al. Preventing cancer, cardiovascular disease, and diabetes:
A common agenda for the American Cancer Society, the American
Diabetes Association, and the American Heart Association. Stroke
2004;35:1999‑2010.
4. Willett WC, Koplan JP, Nugent R, Dusenbury C, Puska P,
Gaziano TA. Prevention of chronic disease by means of diet and
lifestyle changes. In: Jamison DT, Breman JG, Measham AR,
Alleyne G, Claeson M, Evans DB, et al., editors. Disease
Control Priorities in Developing Countries. Washington (DC):
World Bank The International Bank for Reconstruction and
Development/The World Bank Group; 2006.
5. Pickering GW. The natural history of hypertension. Br Med Bull
1952;8:305‑9.
6. World Health Organization. AGlobal Brief on Hypertension: Silent
Killer, Global Public Health Crisis. Geneva, Switzerland:World
Health Organization; 2013.
7. Bromfield S, Muntner P. High blood pressure: The leading
global burden of disease risk factor and the need for worldwide
prevention programs. Curr Hypertens Rep 2013;15:134‑6.
8. Banerjee D, Chung S, Wong EC, Wang EJ, Stafford RS,
Palaniappan LP, et al. Underdiagnosis of hypertension using
electronic health records. Am J Hypertens 2012;25:97‑102.
9. Rocella EJ, Burt V, Horan MJ, Cutler J. Changes in hypertension
awareness, treatment, and control rates 20‑year trend data. Ann
Epidemiol 1993;3:547‑9.
10. Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension
in the United States. Circulation 2005;112:1651‑62.
11. Arredondo A. Hospitalization costs associated with hypertension
as a secondary diagnosis. Am J Hypertens 2010;23:224.
12. Reynolds K, Gu D, Muntner P, Wu X, Chen J, Huang G, et al.
Geographic variations in the prevalence, awareness, treatment
and control of hypertension in China. J Hypertens 2003;21:1273‑81.
13. Zhao B, Jose PO, Pu J, Chung S, Ancheta IB, Fortmann SP, et al.
Racial/ethnic differences in hypertension prevalence, treatment,
and control for outpatients in Northern California 2010‑2012. Am
J Hypertens 2015;28:631‑9.
14. Haghdoost AA, Sadeghirad B, Rezazadehkermani M.
Epidemiology and heterogeneity of hypertension in Iran:
A systematic review. Arch Iran Med 2008;11:444‑52.
15. Ebrahimi M, Mansournia MA, Haghdoost AA, Abazari A,
Alaeddini F, Mirzazadeh A, et al. Social disparities in prevalence,
treatment and control of hypertension in Iran: Second national
surveillance of risk factors of noncommunicable diseases, 2006.
J Hypertens 2010;28:1620‑9.
16. Malekzadeh MM, Etemadi A, Kamangar F, Khademi H,
Golozar A, Islami F, et al. Prevalence, awareness and risk factors
of hypertension in a large cohort of Iranian adult population.
J Hypertens 2013;31:1364‑71.
17. Sarraf‑Zadegan N, Boshtam M, Mostafavi S, Rafiei M. Prevalence
of hypertension and associated risk factors in Isfahan, Islamic
republic of Iran. East Mediterr Health J 1999;5:992‑1001.
18. Azizi F, Ghanbarian A, Madjid M, Rahmani M. Distribution of
blood pressure and prevalence of hypertension in Tehran adult
population: Tehran lipid and glucose study (TLGS), 1999‑2000.
J Hum Hypertens 2002;16:305‑12.
19. Ghorbani R, Askandarian R, Malek M, Rashidy‑Pour A.
Prevalence of hypertension among the adult population of
Semnan province. Iran J Endocrinol Metab 2009;10 (5)498‑503.
20. Physical Status. The Use and Interpretation of Anthropometry.
Technical Report 854. Geneva: WHO; 1995.
21. World Health Organization. Waist Circumference and Waist‑Hip
Ratio: Report of a WHO Expert Consultation. 8‑11 December,
2008. Geneva: World Health Organization; 2011.
22. Mirzaei M, Asghari‑Jafarabadi M, Amini‑Sani N,
Bakhtari‑Aghdam F, Dastgiri S. Psychometric evaluation of a
self‑reported physical activity questionnarie used in the pilot
phase of the AZAR cohort study. Health Promot Perspect
2016;6:152‑8.
23. Aadahl M, Jørgensen T. Validation of a new self‑report
instrument for measuring physical activity. Med Sci Sports Exerc
2003;35:1196‑202.
24. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y,
Rodbard HW, et al. American association of clinical
endocrinologists’ guidelines for management of dyslipidemia
and prevention of atherosclerosis: Executive summary. Endocr
Pract 2012;18:269‑93.
25. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K,
et al. Global disparities of hypertension prevalence and control:
A Systematic analysis of population‑based studies from 90
countries. Circulation 2016;134:441‑50.
26. Yazdanpanah L, Shahbazian H, Shahbazian H, Latifi SM.
Prevalence, awareness and risk factors of hypertension in
Southwest of Iran. J Renal Inj Prev. 2015;4(2):51‑6.
27. Kassaei SA, Valizadeh M, Sokhanvar S, MakoieMD RH.
Hypertension awareness, treatment, control and prevalence in
Zanjan province, Iran. 2010; 11(1):10‑16.
28. Shirani S, Gharipour M, Khosravi A, Kelishadi R, Habibi HR,
Abdalvand A, et al. Gender differences in the prevalence of
hypertension in a representative sample of Iranian population:
The Isfahan healthy heart program. Acta Biomed 2011;82:223‑9.
29. Murphy CM, Kearney PM, Shelley EB, Fahey T, Dooley C,
Kenny RA, et al. Hypertension prevalence, awareness, treatment
and control in the over 50s in Ireland: Evidence from the
Irish longitudinal study on ageing. J Public Health (Oxf)
2016;38:450‑8.
30. Ikeda N, Sapienza D, Guerrero R, Aekplakorn W, Naghavi M,
Mokdad AH, et al. Control of hypertension with medication:
A comparative analysis of national surveys in 20 countries. Bull World Health Organ 2014;92:10‑9C.
31. Musinguzi G, Nuwaha F. Prevalence, awareness and control of
hypertension in Uganda. PLoS One 2013;8:e62236.
32. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A,
et al. Prevalence, awareness, treatment, and control of hypertension
in rural and urban communities in high‑, middle‑, and low‑income
countries. JAMA 2013;310:959‑68.
33. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F,
Poulter N, et al. Hypertension prevalence, awareness, treatment
and control in national surveys from England, the USA and
Canada, and correlation with stroke and ischaemic heart disease
mortality: A cross‑sectional study. BMJ Open 2013;3:e003423.
34. Babiker FA, Elkhalifa LA, Moukhyer ME. Awareness of
hypertension and factors associated with uncontrolled
hypertension in Sudanese adults. Cardiovasc J Afr 2013;24:208‑12.
35. Wang J, Zhang L, Wang F, Liu L, Wang H; China National Survey
of Chronic Kidney Disease Working Group, et al. Prevalence,
awareness, treatment, and control of hypertension in China:
Results from a national survey. Am J Hypertens 2014;27:1355‑61.
36. Farzadfar F, Murray CJ, Gakidou E, Bossert T, Namdaritabar H,
Alikhani S, et al. Effectiveness of diabetes and hypertension
management by rural primary health‑care workers (Behvarz
workers) in Iran: A nationally representative observational study.
Lancet 2012;379:47‑54.
37. Azizi A, Abasi M, Abdoli G. The prevalence of hypertension
and its association with age, sex and BMI in a population being
educated using community‑based medicine in Kermanshah: 2003.
Iran J Endocrinol Metab 2008;10:323‑9.
38. Higashi T, Wenger NS, Adams JL, Fung C, Roland M,
McGlynn EA, et al. Relationship between number of medical
conditions and quality of care. N Engl J Med 2007;356:2496‑504.
)